An Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of ABX464 in HIV-1 Seronegative and Seropositive Adults

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 03 Apr 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

26 Aug 2021 Results evaluating total and intact HIV DNA and the HIV transcription profile before and after ABX464 therapy in available samples from the ABX464-005 study, published in the Clinical Infectious Diseases
11 Mar 2020 Results (n=11) assessing effect of ABX464 on the HIV transcription profile and total and intact HIV DNA in circulating CD4+ T cells from ART-suppressed participants, presented at the 27th Conference on Retroviruses and Opportunistic Infections
22 Jan 2019 Status changed from active, no longer recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com